Camptosar
(irinotecan hydrochloride)Phase 3Small molecule
Irinotecan is a chemotherapy drug used to treat certain types of cancer, particularly colorectal cancer and sometimes lung or ovarian cancer. It works by damaging cancer cells' DNA to stop them from growing and dividing.[1] Camptosar is currently being investigated across 57 indications[3], with its most advanced program in Phase 3.[1]
Camptosar is one of 1033 small molecule programs targeting Glioma. It is currently in Phase 3.
57
Indications
322
Total Trials
16
Active Trials
1,032
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 56 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Camptosar
EEastern Cooperative Oncology Group
Phase 3
Gemzar
GGynecologic Oncology Group
Preclinical
Adenocard
AstellasPreclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Conventional Chemotherapy
SShanghai Jiao Tong University School of Medicine
Preclinical
Lipegfilgrastim
Merck & Co.Preclinical
Leronlimab
CCytoDyn, Inc.
Preclinical
Tetracycline Hydrochloride
EEuropean Organisation for Research and Treatment of Cancer - EORTC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer36 trials
Show 33 more trials
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00064181·86 enrolled
Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Completed·—·Phase 1·NCT01205022·3 enrolled
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00004885·430 enrolled
Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00003260·109 enrolled
Colorectal Cancer23 trials
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
Unknown status·—·Phase 2·NCT00513266·35 enrolled
Show 20 more trials
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
Not yet recruiting·—·Phase 3·NCT07271355·129 enrolled
Pancreatic Cancer11 trials
Show 8 more trials
Non-Small Cell Lung Cancer9 trials
Show 6 more trials
Small Cell Lung Cancer8 trials
Show 5 more trials
60 more indications
Patients With Advanced Solid Tumors6 trials
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
Completed·—·Phase 1·NCT00002902
Show 3 more trials
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Completed·—·Phase 1·NCT00006465·22 enrolled
Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00003710·12 enrolled
Rhabdomyosarcoma6 trials
Show 3 more trials
Esophageal Cancer5 trials
Refractory Solid Tumors5 trials
Breast Cancer5 trials
Glioblastoma Multiforme4 trials
Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy
Completed·—·Phase 2·NCT00039468·26 enrolled
Radiation Therapy4 trials
Malignant Glioma4 trials
Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma
Completed·—·Phase 1·NCT00002988·36 enrolled
Show 1 more trial
Glioma4 trials
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
Completed·—·Phase 1·NCT00003463
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
Completed·—·Phase 2·NCT00268359·68 enrolled
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
Active, not recruiting·—·Phase 1·NCT02192359·18 enrolled
Show 1 more trial
Metastatic Solid Tumors3 trials
Locally Advanced or Metastatic Solid Tumors3 trials
Gastric Cancer3 trials
Lymphoma3 trials
Patients With Solid Tumors3 trials
Intestinal Cancer3 trials
Gastroesophageal Junction Cancer2 trials
Advanced Solid Tumors2 trials
Locally Advanced2 trials
Cancer of the Esophagus2 trials
Soft Tissue Sarcoma2 trials
Neuroblastoma2 trials
Esophageal Squamous Cell Carcinoma1 trial
Bile Duct Cancer1 trial
Cancer of the Stomach1 trial
Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus
Unknown status·—·Phase 2·NCT00005607
Chemotherapy1 trial
Triple-Negative Breast Cancer1 trial
Ewing sarcoma1 trial
Cancer of Unknown Primary1 trial
Stage IV Rectal Cancer1 trial
Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer
Unknown status·—·Phase 1·NCT00392470·20 enrolled
Refractory or Recurrent Solid Tumor1 trial
Chronic Myelogenous Leukemia1 trial
Adenocarcinoma1 trial
Biliary Tract Cancer1 trial
Locally-advanced Rectal Cancer1 trial
Recurrent Cancer1 trial
Peritoneal Cancer1 trial
Primary Brain Tumor1 trial
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Completed·—·Phase 1·NCT00003484·21 enrolled
HER2-Positive Solid Tumor1 trial
First Line Therapy1 trial
Penile Cancer1 trial
Rectal Cancer1 trial
Low Grade Glioma1 trial
Thyroid Cancer1 trial
Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00100828·6 enrolled
Colorectal Carcinoma1 trial
Squamous Cell Carcinoma1 trial
Unresectable Solid Tumor1 trial
Gastroesophageal Junction1 trial
Glioblastoma1 trial
Radiosurgery Plus Bevacizumab in Glioblastoma
Terminated·—·Phase 1·NCT01086345·9 enrolled
Stomach Cancer1 trial
Brain Metastases From Solid Tumors1 trial
Stage II Colon Cancer1 trial
Gastroesophageal Junction Carcinoma1 trial
Pancreatic Adenocarcinoma1 trial
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
Terminated·—·Phase 2·NCT02345460·1 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for irinotecan hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details